Crispr Therapeutics AG (NASDAQ:CRSP) has been given a consensus rating of “Buy” by the eighteen ratings firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have given a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $72.86.
A number of brokerages have commented on CRSP. ValuEngine cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. Goldman Sachs Group raised their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. BidaskClub cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 1st. Roth Capital raised their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th.
CRSP stock traded up $0.51 during mid-day trading on Monday, reaching $59.95. The company’s stock had a trading volume of 1,011,477 shares, compared to its average volume of 1,376,743. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -17.43 and a beta of 3.20. The business’s 50 day moving average price is $66.14 and its 200 day moving average price is $51.34. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics has a 12 month low of $29.34 and a 12 month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, equities analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock valued at $3,620,760 in the last three months. Insiders own 21.40% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Nikko Asset Management Americas Inc. boosted its position in shares of Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the last quarter. Orbimed Advisors LLC purchased a new position in shares of Crispr Therapeutics during the third quarter valued at approximately $21,167,000. Finally, Morgan Stanley boosted its position in shares of Crispr Therapeutics by 6.1% during the second quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after buying an additional 16,361 shares during the last quarter. 49.82% of the stock is currently owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.